B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Won, Jong Ho | - |
dc.date.accessioned | 2021-08-12T03:46:01Z | - |
dc.date.available | 2021-08-12T03:46:01Z | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.issn | 1029-2403 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15463 | - |
dc.description.abstract | Chronic graft-versus-host disease (GVHD) is a serious complication that develops frequently in survivors of allogeneic stem cell transplant. Since elucidation of the role of B cells in the pathogenesis of chronic GVHD, B cell-depleting therapy with rituximab has been associated with beneficial effects in clinical and laboratory studies in patients with chronic GVHD. Although the mechanism underlying the contribution of B cells to the development of chronic GVHD is poorly understood, recent studies have proposed that B cell reconstitution after allogeneic stem cell transplant is involved in the development of chronic GVHD. Inadequate reconstitution of naive B cells and the persistence of high levels of B cell-activating factor have been found in patients with chronic GVHD, and these changes might be associated with the expansion of activated CD27-positive B cells that produce autoantibody in chronic GVHD. In the light of this altered B cell homeostasis in chronic GVHD, the role of rituximab in controlling the clinical manifestations of chronic GVHD has been studied. In this review, we address the role of B cells in the pathogenesis of chronic GVHD and the response to B cell-depleting therapy based on B cell homeostasis. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Taylor & Francis | - |
dc.title | B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.3109/10428194.2011.603448 | - |
dc.identifier.scopusid | 2-s2.0-84855435165 | - |
dc.identifier.wosid | 000298750700005 | - |
dc.identifier.bibliographicCitation | Leukemia and Lymphoma, v.53, no.1, pp 19 - 25 | - |
dc.citation.title | Leukemia and Lymphoma | - |
dc.citation.volume | 53 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 19 | - |
dc.citation.endPage | 25 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | MINOR HISTOCOMPATIBILITY ANTIGENS | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY TREATMENT | - |
dc.subject.keywordPlus | BONE-MARROW TRANSPLANTATION | - |
dc.subject.keywordPlus | REFRACTORY CHRONIC GVHD | - |
dc.subject.keywordPlus | EXCESS BAFF | - |
dc.subject.keywordPlus | KAPPA-B | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | LYMPHOCYTES | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | chronic GVHD | - |
dc.subject.keywordAuthor | allogeneic stem cell transplant | - |
dc.subject.keywordAuthor | B cell homeostasis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.